Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of bleeding episodes in patients with haemophilia A. The present investigations from the multinational, open-label guardian™ clinical trials assessed the haemostatic response of...

Full description

Bibliographic Details
Main Authors: Santagostino, E, Lentz, S R, Misgav, M, Brand, B, Chowdary, P, Savic, A, Kilinc, Y, Amit, Y, Amendola, A, Solimeno, L P, Saugstrup, T, Matytsina, I
Format: Online
Language:English
Published: Blackwell Publishing Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309503/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309503/

Similar Items